HIV SeropositivityCell SurvivalHIV SeroprevalenceHIV InfectionsSubstance Abuse, IntravenousSexual BehaviorRisk FactorsDisease ProgressionSeroepidemiologic StudiesSurvival RateDisease-Free SurvivalAntibodies, ViralSurvival AnalysisAntibodies, BacterialChlamydophila pneumoniaeSurvivalImmunoglobulin GChlamydophila InfectionsEnzyme-Linked Immunosorbent AssaySerologic TestsTime FactorsTreatment OutcomeGraft SurvivalHIV SeronegativityPrevalenceRetrospective StudiesFollow-Up StudiesHelicobacter pyloriHelicobacter InfectionsCohort StudiesProspective StudiesAcquired Immunodeficiency SyndromeHIV-1ToxocariasisAge FactorsCase-Control StudiesMultivariate AnalysisCytomegalovirus InfectionsAntibodies, ProtozoanPrognosisKaplan-Meier EstimateCross-Sectional StudiesToxoplasmosisCell Line, TumorProportional Hazards ModelsHepatitis CApoptosisHerpesvirus 2, HumanToxocaraNeoplasm StagingAIDS SerodiagnosisBlood DonorsPapillomavirus InfectionsCell CycleSignal TransductionCD4 Lymphocyte CountImmunohistochemistryOdds RatioNeosporaIncidenceCytomegalovirusRural PopulationAdenocarcinomaCell ProliferationBrazilNeoplasm MetastasisHuman papillomavirus 16Immunoglobulin AHerpes GenitalisToxoplasmaAntineoplastic Combined Chemotherapy ProtocolsGene Expression Regulation, NeoplasticBreast NeoplasmsSyphilisBlotting, WesternImmunoglobulin MHomosexualityTumor Markers, BiologicalAnti-HIV AgentsLogistic ModelsViral LoadLung NeoplasmsHomosexuality, MaleAntineoplastic AgentsHepatitis B